Skip to main content
Clinical Trials/NCT01368302
NCT01368302
Completed
Phase 2

Attention Bias Modification Treatment (ABMT) for Patients With Post Traumatic Stress Disorder (PTSD)

Tel Aviv University1 site in 1 country52 target enrollmentJuly 2011

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Attention Bias Modification Treatment (ABMT)
Sponsor
Tel Aviv University
Enrollment
52
Locations
1
Primary Endpoint
Clinician-Administered PTSD Scale (CAPS)
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

Patients with Post Traumatic Stress Disorder (PTSD) will be randomly assigned to either Attention Bias Modification Treatment (ABMT) designed to normalize threat-related attention biases or a placebo control condition not designed to change attention patterns. Outcome measures will be Post Traumatic Stress Disorder (PTSD), depression, and anxiety symptoms as measured by gold standard questionnaires and symptom counts derived from structured clinical interviews.

We expect to see significant Post Traumatic Stress Disorder symptom reduction in the Attention Bias Modification Treatment (ABMT) group relative to the placebo control group in which no symptomatic relief is expected.

Registry
clinicaltrials.gov
Start Date
July 2011
End Date
March 2013
Last Updated
11 years ago
Study Type
Interventional
Study Design
Factorial
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Yair Bar-Haim

Professor

Tel Aviv University

Eligibility Criteria

Inclusion Criteria

  • Combat-related PTSD diagnosis

Exclusion Criteria

  • Other treatment

Outcomes

Primary Outcomes

Clinician-Administered PTSD Scale (CAPS)

Time Frame: 40 minutes

The clinician-Administered PTSD Scale (CAPS) is a 30-item structured interview that corresponds to the DSM-IV criteria for PTSD (Blake, Weathers, Nagy, Kaloupek, Charney, \& Keane, 1995).

Secondary Outcomes

  • PTSD Check List (PCL)(10 minutes)

Study Sites (1)

Loading locations...

Similar Trials